Tyrosinemia type I

A rare genetic disorder affecting tyrosine metabolism

Tyrosinemia type I is a rare autosomal recessive genetic disorder that affects the metabolism of the amino acid tyrosine. It is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), which is the last enzyme in the tyrosine catabolic pathway. This deficiency leads to the accumulation of toxic metabolites, causing severe liver and kidney dysfunction.

Pathophysiology

Metabolic pathway affected in Tyrosinemia type I

In Tyrosinemia type I, the deficiency of FAH results in the accumulation of fumarylacetoacetate, which is converted to succinylacetone. Succinylacetone is a toxic compound that inhibits porphobilinogen synthase, leading to porphyria-like symptoms. The accumulation of these metabolites causes damage to the liver and kidneys, leading to hepatorenal syndrome.

Genetics

Tyrosinemia type I is inherited in an autosomal recessive pattern

Tyrosinemia type I is inherited in an autosomal recessive manner. This means that an affected individual must inherit two copies of the defective gene, one from each parent. The gene responsible for Tyrosinemia type I is located on chromosome 15q23-q25 and is known as the FAH gene.

Symptoms

Symptoms of Tyrosinemia type I typically appear in infancy and may include failure to thrive, jaundice, hepatomegaly, renal tubular acidosis, and rickets. If untreated, the condition can lead to liver failure, renal failure, and an increased risk of hepatocellular carcinoma.

Diagnosis

Diagnosis of Tyrosinemia type I is based on clinical symptoms, biochemical tests showing elevated levels of tyrosine and succinylacetone in the blood and urine, and genetic testing to confirm mutations in the FAH gene.

Treatment

Structure of Nitisinone, a drug used in the treatment of Tyrosinemia type I

The primary treatment for Tyrosinemia type I is the use of nitisinone, a drug that inhibits the enzyme 4-hydroxyphenylpyruvate dioxygenase, thereby reducing the production of toxic metabolites. Dietary management with a low-tyrosine and low-phenylalanine diet is also essential. In severe cases, liver transplantation may be necessary.

Prognosis

With early diagnosis and treatment, individuals with Tyrosinemia type I can have a significantly improved prognosis. Nitisinone therapy has been shown to prevent liver and kidney damage and reduce the risk of liver cancer.

Related pages

• Tyrosinemia
• Inborn errors of metabolism
• Phenylketonuria

References

• Grompe, M. (2001). "The pathophysiology and treatment of hereditary tyrosinemia type 1." Seminars in Liver Disease, 21(4), 563-571.
• Lindstedt, S., et al. (1992). "Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase." The Lancet, 340(8823), 813-817.

• 
  Tyrosinemia type I metabolic pathway
• 
  Autosomal recessive inheritance pattern
• 
  Tyrosine metabolic pathway
• 
  Tyrosine WPMP
• 
  Nitisinone structure